

Study of RANTES Promoter Polymorphism in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients

Thesis

*Submitted for Partial Fulfillment of
M.D. Degree in Clinical and Chemical Pathology*

By

Rasha Mohamad Hosny Shahin
M.B.B.Ch., M.Sc., Cairo University

Supervised by

Prof. Dr. Omayma Abdel Kader Gohar

*Professor of Clinical and Chemical Pathology
Faculty of Medicine
Cairo University*

Prof. Dr. Mona Salah El-Din Hamdy

*Professor of Clinical and Chemical Pathology
Faculty of Medicine
Cairo University*

Dr. Rasha El Sayed Gheith

*Lecturer of Rheumatology and Rehabilitation
Faculty of Medicine
Cairo University*

**Faculty of Medicine
Cairo University
2009**



Abstract

Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease of the joints. Systemic lupus erythematosus (SLE) is an autoimmune disease which has the potential to involve multiple organs. There are several lines of evidence that chemokines play an important role in the inflammatory development and progression of autoimmune diseases. RANTES is a chemokine that is member of the CC chemokines.

The aim of the work was to evaluate the possible effect of the RANTES gene on the susceptibility to RA and SLE by examining the polymorphism of promoter at position -403 of this gene in RA and SLE patients and ethnically matched controls.

Subjects and methods: The study included 32 rheumatoid arthritis patients and 32 systemic lupus erythematosus patients. Thirty sex and age matched healthy individuals were also included in the study as a control group. All patients were subjected to: careful history taking, assessment of disease activity, laboratory investigations as well as RANTES-403 genotyping by PCR-RFLP.

Results: RANTES -403 A/A genotype frequency was significantly higher in RA (18.75%) and SLE (15.63 %) in comparison to healthy individuals (0%) ($p=0.038$ and $p=0.037$ respectively). However, No significant association was found between clinical aspects and RANTES polymorphism.

Conclusion: These findings suggest that the presence of the A allele in position -403 in the RANTES gene may be a possible risk factor in the pathogenesis of SLE and RA .

The use of RANTES gene therapy appears to be a promising line of treatment for RA and SLE patients.

Key words: Rheumatoid arthritis- Systemic lupus erythematosus- Chemokines- RANTES –gene polymorphism-- PCR-RFLP.

TABLE OF CONTENTS

	Page
List of Abbreviations	III
List of Figures	VIII
List of Tables	IX
Introduction & Aim of the Work	1
Review of Literature	4
Chapter 1: Rheumatoid Arthritis.....	4
• Definition.....	4
• Epidemiology and incidence.....	4
• Risk factors.....	4
• Aetiology.....	5
• Synovial pathophysiology.....	8
• Synovial immune response in RA.....	11
• Regulatory T cells in RA.....	16
• Clinical features.....	18
• Diagnostic criteria.....	24
• Differential diagnosis.....	25
• Investigations.....	26
• Management.....	30
Chapter 2: Systemic Lupus Erythematosus.....	37
• Definition.....	37
• Epidemiology.....	37
• Determinants of disease susceptibility.....	38
• Pathogenesis.....	42
• Clinical manifestations.....	50
• Laboratory tests.....	54

• Diagnostic criteria.....	60
• Management of SLE.....	61
Chapter 3: Chemokines.....	62
• Definition.....	62
• Classification.....	62
• Signal transduction pathways	64
• Members of chemokine families.....	65
• Role of chemokines in leukocyte movement.....	71
• Role of chemokines in inflammatory diseases.....	72
• Role of chemokines in infectious diseases	79
• Modulation of angiogenesis, tumor growth, and stem-cell proliferation.....	81
• RANTES.....	82
• Immunological assays for chemokine detection.....	87
• Strategies to control the chemokine system.....	90
Subjects and Methods	94
Results	106
Discussion	132
Summary	140
References	142
Arabic Summary	

ABBREVIATIONS

ACRSRA	The American College of Rheumatology Subcommittee on Rheumatoid Arthritis
ANA	Antinuclear antibodies
APC	Antigen presenting cell
APL	Antibodies to phospholipids
BCA-1	B-cell chemoattractant 1
bp	Base pair
CCP	Cyclic citrullinated peptide
CD	Cluster of differentiation
CHAK	CC-Chemokine-activated killer
Chond/OC	Chondrocytes and osteoclasts
CIA	Collagen induced arthritis
CNS	Central nervous system
COPD	Chronic obstructive pulmonary disease
CR1	Complement receptor 1
CRP	C-reactive protein
CTACK	Cutaneous T-cell- attracting chemokine
CTLA-4	Cytotoxic T lymphocyte antigen -4
DAG	Diacyl glycerol
DARC	Duffy antigen receptor for chemokines
DAS	Disease activity score
DMARD	Disease modifying anti rheumatic drug
DNA	Deoxy-ribonucleic Acid

EBV	Epstein barr virus
ECG	Electrocardiography
EDTA	Ethylene diamine tetracetic acid
ELISPOT	Enzyme-linked immunospot
ENA	Epithelial cell-derived neutrophil-activating peptide
ESR	Erythrocyte sedimentation rate
Fab	Antigen-binding fragment
Fc	Fragment crystallisable
FcγR	Fragment crystallisable gamma receptor
FLS	Fibroblast-like synoviocytes
Foxp3	Forkhead box p3
GCP	Granulocyte chemotactic protein
G-CSF	Granulocyte colony stimulating factor
GM-CSF	Granulocyte-monocyte colony stimulating factor
GPCRs	G protein–coupled receptors
GRO	Growth-regulated oncogene
GRO-α	Growth-related oncogene α
HB	Haemoglobin
HCC	Hemofiltrate chemokine
HIV	Human immunodeficiency virus
HLA	Human leucocyte antigen
HRT	Hormonal replacement therapy
ICOS	Inducible costimulator
IFN	Interferon

Ig	Immunoglobulin
IL	Interleukin
IP-10	Interferon-inducible protein 10
I-TAC	Interferon-inducible T-cell alpha chemoattractant
KDa	Kilo-dalton
LAG3	Lymphocyte activation gene 3
LARC	Liver and activation-related chemokine
LFA	lymphocyte function-associated antigen
LH	luteinizing hormone
MBP	Mannose binding protein
MCAF	Monocyte chemotactic and activating factor
MCP	Metacarpopharyngeal
MCP	Monocyte chemotactic protein
MDC	Macrophage-derived chemokine
MEC	Mammary-enriched chemokine
MHC	Major histocompatibility complex
MIG	Monokine induced by interferon- γ
MIP-1	macrophage inflammatory protein-1
MIP-3α	Macrophage inflammatory protein-3 alpha
Mono/Mac	Monocytes and macrophages
mRNA	Messenger ribonucleic acid
MS	Morning stiffness
MTP	Metatarsopharyngeal
NMDA	N-methyl-D-aspartate

NSAID	Non steroidal anti-inflammatory drug
PCR	Polymerase chain reaction
PF	Platelet factor
PI3Kγ	Phosphatidylinositol-3'-kinase γ
PIP	Proximal interpharyngeal
PLC	Phospholipase-C
RA	Rheumatoid arthritis
RANK	Receptor activator of nuclear factor-kappa B
RANTES	Regulated upon activation, normal T-cell expressed and secreted
RF	Rheumatoid factor
RFLP	Restriction fragment length polymorphism
RNP	Ribonucleoprotein
SCLE	Subacute cutaneous lupus erythematosus
SD	Standard deviation
SDF	Stromal-cell-derived factor
SE	Shared epitope
SJC	Swollen joint count
SLC	Secondary lymphoid tissue chemokine
SLE	Systemic lupus erythematosus
SLEDAI	SLE Disease Activity Index
Sm	Smith
SNP_s	single nucleotide polymorphisms
SR-PSOX	Scavenger receptor for phosphatidylserine-containing oxidized lipids

T reg	Regulatory T
TARC	Thymus and activation-related chemokine
TCR	T cell receptor
TECK	Thymus-expressed chemokine
TGF-β	Transforming growth factor Beta
Th	T helper
TJC	Tender joint count
TLC	Total leukocytic count
TNF	Tumor necrosis factor
UV light	Ultra violet light
VEGF	Vascular endothelial growth factor

LIST OF FIGURES

Figures		Page
1	Aetiology of RA	5
2	Synovial pathophysiology in RA	10
3	Schematic diagram of the putative interactions of pathogenic Th17 cells in the synovial microenvironment.	17
4	Induction of surface blebs during apoptosis	46
5	The pathogenesis of systemic lupus erythematosus.	49
6	Chemical structure of chemokine families	63
7	Human chemokines and their receptors.	68
8	Role of chemokines in various inflammatory diseases	78
9	Chemokine receptors as obligate co-receptors for HIV entry into cells, and chemokines inhibiting M-tropic and T-tropic HIV entry	80
10	Comparison of RANTES genotypes between RA patients and control group	123
11	Radiological assesement of the patients	123
12	Clinical data of SLE patients	130
13	Comparison of RANTES genotypes between SLE patients and control group	130
14	Gel electrophoresis showing genotypes of RANTES gene promoter region at -403	131

LIST OF TABLES

Tables		Page
1	Effector molecules induced by IL-17 from human cells	15
2	Differential Diagnosis of Rheumatoid Arthritis	25
3	DMARDs for Treatment of Rheumatoid Arthritis	32-36
4	Classification criteria for the diagnosis of systemic lupus erythematosus (SLE)	60
5	CC family and chemokine receptors	69
6	CXC, CX ₃ C and XC families of chemokines and chemokine receptors	70
7	Immunological assays for chemokine detection	87
8	X- ray staging of the patients	95
9	SLE Disease Activity Index (SLEDAI)	96
10	Reaction composition using Taq PCR Master Mix	101
11	Clinical data of the RA patients	115
12	The laboratory data of the RA patients	116
13	Statistical analysis of the clinical data of RA patients	117
14	Statistical analysis of the clinical data of RA patients	117
15	Radiological assessment of RA patients	118
16	Statistical analysis of the laboratory data of RA patients	118
17	Statistical analysis of the laboratory data of RA patients	118
18	Frequency of the RANTES -403 genotypes in RA patients and controls	119
19	The clinical characteristics of RA patients in relation to RANTES genotypes	119
20	The laboratory characteristics of RA patients in relation to RANTES genotypes	120

21	The radiological assesement of RA patients in relation to RANTES genotypes	120
22	Clinical Characteristics of patients According to RA severity as assessed by DAS 28	121
23	Laboratory characteristics of the patients According to RA severity as assessed by DAS28	122
24	Clinical data of the SLE patients	124
25	The laboratory data of the SLE patients	125
26	Statistical analysis of the clinical data of SLE patients	126
27	Statistical analysis of the clinical data of SLE patients	126
28	Statistical analysis of the laboratory data of SLE patients	127
29	Statistical analysis of the laboratory data of SLE patients	127
30	Frequency of the RANTES -403 genotypes in SLE patients and controls	127
31	The clinical characteristics of SLE patients in relation to RANTES genotypes	128
32	Comparison of genotypes and alleles of RANTES -403 locus between renal damage and no renal damage	129
33	The laboratory characteristics of SLE patients in relation to RANTES genotypes	129

ACKNOWLEDGEMENT

First and foremost thanks to "God" the source of all good.

Then I would like to express my deep thanks and appreciation to Prof. Dr. Omayma Abdel Kader Gohar; professor of Clinical and Chemical Pathology, faculty of medicine, Cairo university, for giving me a lot of her precious time and support and for her constructive guidance and valuable observations.

I am also grateful to Prof. Dr. Mona Salah El-Din Hamdy; professor of Clinical and Chemical Pathology, faculty of medicine, Cairo university, for her great help, continuous supervision and effort with me throughout this study. She supplied me with valuable information which were important pillars in my thesis.

My sincere appreciation to Dr. Rasha El Sayed Gheith; lecturer of Rheumatology and Rehabilitation, faculty of medicine, Cairo university. She kindly guided my steps and was always providing me with valuable suggestions, advice, experience and constant support which were the cornerstone in the completion of this study.

I wish to thank all my patients, without whom this work would have never been completed.

Finally whatever I say will never be enough to thank my husband and family, I greatly appreciate their moral help, they were always supplying me with the feeling of hope, love and encouragement.

This thesis is dedicated to a great and special father, mother, aunt and uncle. It is also dedicated to a cooperative kind husband and to my beloved family.

Introduction

Chemotactic cytokines (chemokines) are small signaling proteins that are released by a variety of cells and are involved in the pathophysiology of inflammatory processes, through the process of attracting and stimulating specific subsets of leucocytes. (*Liao et al., 2004*)

Chemokines, such as regulated upon activation, normal T cell expressed and secreted (RANTES) are responsible for the recruitment of monocytes and T lymphocytes in both the acute and chronic phases of inflammation. (*Rovin and Phan, 1998*)

RANTES is produced from various cell types, including CD8+T cells, CD4+T cells, monocyte/macrophages and renal tubular epithelium after cellular activation by stimuli and cytokines such as tumor necrosis factor- α and interleukin 1 β stimulation. (*Canque et al., 1996*)

The RANTES gene is located on human chromosome 17. Two single nucleotide polymorphisms (SNPs) in the RANTES promoter region (-28C \rightarrow G and -403G \rightarrow A) have been found affecting the transcription of RANTES gene. (*Mehrabian et al., 1991*)

In human cell lines the -28G and the -403 A were shown to increase promoter activity of RANTES compared to the more frequent -28C and the -403G, respectively, suggesting that these polymorphisms increase RANTES expression in the human body. (*Liu et al., 1999*)

Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease with synovial tissue invasion by inflammatory cells. These cells and associated products such as chemokines play an essential role in synovitis, pannus formation and eventually joint destruction. (*Szekanecz et al., 2003*)